Active ingredientLamivudineCat. No. P-L009-001CAS 134678-17-4Family · Pharmaceutical analytical standards
Lamivudine
A nucleoside reverse transcriptase inhibitor, also known as 3TC, approved in the United States in 1995: it is used against HIV, in combination with other antiretrovirals, and against chronic hepatitis B. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?It was created between 1988 and 1989 in Montreal, Canada, through the work of Bernard Belleau and Paul Nguyen-Ba; the code 3TC recalls its chemical name 3'-thiacytidine, because a sulphur atom sits in the sugar ring.
Go to the active ingredient →Active ingredientLamivudineCat. No. P-L009-001CAS 134678-17-4
Pharmacopoeial impurityLamivudine AcidCat. No. P-L009-002CAS 173829-09-9
Pharmacopoeial impurityLamivudine EP Impurity ACat. No. P-L009-003CAS 173602-25-0
Pharmacopoeial impurityLamivudine EP Impurity BCat. No. P-L009-005CAS 136846-20-3
Pharmacopoeial impurityLamivudine EP Impurity D (Lamivudine Enantiomer)Cat. No. P-L009-006CAS 134680-32-3
Pharmacopoeial impurityLamivudine EP Impurity ECat. No. P-L009-007CAS 71-30-7
Pharmacopoeial impurityLamivudine EP Impurity GCat. No. P-L009-008CAS 160552-55-6
Pharmacopoeial impurityLamivudine EP Impurity HCat. No. P-L009-009CAS 160552-54-5
Pharmacopoeial impurityLamivudine EP Impurity I (mixture of enantiomers)Cat. No. P-L009-010CAS 145511-98-4
Pharmacopoeial impurityLamivudine EP Impurity ICat. No. P-L009-011CAS 145918-75-8
Pharmacopoeial impurityLamivudine EP Impurity JCat. No. P-L009-012CAS 145986-07-8
Isotopically labelledLamivudine-13C-15N2 (Mixture of Enantiomers)Cat. No. P-L009-015CAS 1217746-03-6
NitrosamineN-Nitroso Lamivudine EP Impurity JCat. No. P-L009-017
ImpurityLamivudine Impurity 1Cat. No. P-L009-018CAS 147126-80-5
ImpurityLamivudine Impurity 2Cat. No. P-L009-019CAS 1638744-50-9
Impurity5'-epi LamivudineCat. No. P-L009-020CAS 139757-68-9
ImpurityLamivudine DimerCat. No. P-L009-022
ImpurityLamivudine Dimer ImpurityCat. No. P-L009-023
ImpurityLamivudine Impurity 3Cat. No. P-L009-026
ImpurityLamivudine Impurity 4Cat. No. P-L009-027CAS 200396-19-6
ImpurityLamivudine Impurity 5Cat. No. P-L009-028
ImpurityLamivudine Impurity 7Cat. No. P-L009-030CAS 147027-10-9
ImpurityLamivudine Impurity 8Cat. No. P-L009-031CAS 1904611-15-9
ImpurityLamivudine Impurity 9Cat. No. P-L009-032CAS 200396-21-0
ImpurityLamivudine Impurity 10Cat. No. P-L009-033CAS 147126-72-5
ImpurityLamivudine Impurity 11Cat. No. P-L009-034CAS 288325-76-8
ImpurityLamivudine Impurity 12Cat. No. P-L009-036CAS 147027-08-5
ImpurityLamivudine Impurity 13Cat. No. P-L009-037CAS 147126-64-5
ImpurityLamivudine Impurity 14Cat. No. P-L009-038CAS 147126-63-4
ImpurityLamivudine Impurity 15Cat. No. P-L009-039CAS 147126-62-3
ImpurityLamivudine Impurity 16Cat. No. P-L009-040CAS 1309459-32-2
ImpurityLamivudine Mono POC ImpurityCat. No. P-L009-042
ImpurityLamivudine Impurity 17Cat. No. P-L009-043CAS 145416-37-1
ImpurityLamivudine SalicylateCat. No. P-L009-044CAS 173522-96-8
Impurityrac-cis-LamivudineCat. No. P-L009-045CAS 136891-12-8No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substanceLamivudine CRSEDQM code Y0000425Family LamivudineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.